If you are wondering how long to stay on semaglutide, the answer starts with a different question: why did you start? Many people picture a straight line of take the drug, lose the weight, stop. In practice there are two phases with different goals. Induction is about losing weight. Maintenance is about keeping that weight off and protecting your health, and each phase needs its own decisions.
There is no single answer to how long to stay on semaglutide. Here is how to weigh the decision with your doctor, based on your goals and what the trials actually tested.
Why how long has no single answer
The reason you take the drug shapes the timeline. Someone with excess weight and a related condition, such as high blood pressure or sleep apnea, is being treated for a chronic problem, not finishing a short project. Someone using semaglutide for type 2 diabetes usually follows a plan with no set end date. Your prescriber sets the frame based on your indication.
The product matters as well. Wegovy and Ozempic carry different indications, and the wording of each leaflet can change over time. Open the current leaflet for the exact product you use in ANVISA's consultation portal and read the indication and dosing sections yourself, instead of relying on what a friend or a forum says.
Sigue el nivel estimado de cada dosis y sabe cuándo aplicar.
Verlo en la appWhat the clinical trials actually tested about stopping
The STEP 1 trial, led by Wilding and colleagues and published in the New England Journal of Medicine in 2021, followed adults with obesity, or with overweight plus at least one weight-related condition, for 68 weeks. Participants received semaglutide 2.4 mg along with diet and exercise support. Average weight loss was 14.9% in the semaglutide group, compared with 2.4% in the placebo group. Those numbers describe induction, not what happens afterward.
Questions about stopping came from follow-up studies. In an extension of STEP 1, reported by Rubino and colleagues in Lancet Diabetes & Endocrinology in 2022, participants who switched to placebo regained part of the weight they had lost. Read the paper for the exact figure, because summaries tend to round it in ways that blur the picture.
STEP 4, reported by Rubino and colleagues in JAMA in 2021, used a different design. Everyone started with a lead-in period on semaglutide and lost weight. Then they were randomized to keep the drug or switch to placebo. The switch group regained weight, while the continuation group kept more of their loss. In these studies, weight stayed lower as long as treatment continued.
These trials have limits. Participants were carefully selected, followed closely and supported with structured lifestyle programs. Most people taking the drug day to day do not get that level of monitoring or coaching. Treat the results as a description of controlled conditions, not a forecast for your body.